Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an asset acquisition agreement with South Korean biopharmaceutical company Celltrion (KRX: 068270). The deal focuses on 14 branded products across various pan-Asia countries and regions, as well as the Marketing Authorization Holder (MAH) rights for these products in 8 countries and regions, including South Korea, Singapore, Thailand, Australia, and China Hong Kong S.A.R. This strategic acquisition is set to establish Hasten Bio’s presence in Asia, enrich its product portfolio outside of mainland China, and lead to the development of a global supply chain and quality management system. The financial details of the transaction were not disclosed.
The Celltrion products included in this deal address conditions such as hypertension and diabetes, and include well-known medications like Edarbi (azilsartan) for hypertension, Basen (voglibose) for diabetes, Actos (pioglitazone) for diabetes, Blopress (candesartan cilexetil) for hypertension, and Nesina (alogliptin) for diabetes. Hasten Bio considers this acquisition a significant strategic move towards building a robust portfolio in chronic disease and critical illness treatments.- Flcube.com
